FORT LEE, N.J., Oct. 9, 2025 /PRNewswire/ -- Kedrion Biopharma is proud to announce the U.S. availability of YIMMUGO (Immune Globulin Intravenous, Human-dira, 10%), marking a major milestone in the ...

We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. Grifols, S.A. (NASDAQ:GRFS) is among the ...

Dreieich, Germany, October 2, 2024. Following the agreement of binding terms in July, the parties have now finalized all contractual terms and Biotest, part of the Grifols Group, has entered into a ...

The acute SBI rate was 0.07 during the 12-month study period, which met the predefined success rate of less than 1 acute SBI per patient per year. The Food and Drug Administration (FDA) has approved ...

ARLINGTON, Texas--(BUSINESS WIRE)--AOM Infusion (“AOM”), a leading provider of specialty infusion and pharmacy services for chronic and complex conditions, has been selected by Kedrion Biopharma as a ...

Kedrion Biopharma Inc., a biopharmaceutical company, announced that it has established the framework for a long-term agreement with Biotest AG for the full commercialization and distribution of the ...

FDA approval secures significant future sales and earnings growth through entry into the world's largest market Manufactured at Biotest's state-of-the-art, FDA-certified “Next Level” facility in ...

BARCELONA, Spain, June 17, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), one of the world’s leading producers of plasma-derived medicines, today announced that Biotest, a Grifols ...

Dreieich, Germany, October 9, 2025. Biotest AG, a specialist in innovative haematology, clinical immunology and intensive care medicine and part of Grifols, a global healthcare company and leading ...

The issuer is solely responsible for the content of this announcement. Generation) has now also received approval in the United Kingdom for the treatment of patients with congenital and acquired ...

Yimmugo is the first Biotest medicine to be commercialized in the U.S. from its new FDA-certified "Next Level" production facility in Dreieich, Germany, which is already approved for production and ...